Literature DB >> 22352942

Provisional biopharmaceutical classification of some common herbs used in Western medicine.

Sarah Waldmann1, May Almukainzi, Nadia Araci Bou-Chacra, Gordon L Amidon, Beom-Jin Lee, Jianfang Feng, Isadore Kanfer, Joan Zhong Zuo, Hai Wei, Michael B Bolger, Raimar Löbenberg.   

Abstract

The aim of this study was to classify some markers of common herbs used in Western medicine according to the Biopharmaceutical Classification System (BCS). The BCS is a scientific approach to classify drug substances based upon their intestinal permeability and their solubility, at the highest single dose used, within the physiologically relevant pH ranges. Known marker components of twelve herbs were chosen from the USP Dietary Supplement Compendium Monographs. Different BCS parameters such as intestinal permeability (P(eff)) and solubility (C(s)) were predicted using the ADMET Predictor, which is a software program to estimate biopharmaceutical relevant molecular descriptors. The dose number (D₀) was calculated when information from the literature was available to identify an upper dose for individual markers. In these cases the herbs were classified according to the traditional BCS parameters using P(eff) and D₀. When no upper dose could be determined, then the amount of a marker that is just soluble in 250 mL of water was calculated. This value, M(x), defines when a marker is changing from highly soluble to poorly soluble according to BCS criteria. This biopharmaceutically relevant value can be a useful tool for marker selection. The present study showed that a provisional BCS classification of herbs is possible but some special considerations need to be included into the classification strategy. The BCS classification can be used to choose appropriate quality control tests for products containing these markers. A provisional BCS classification of twelve common herbs and their 35 marker compounds is presented.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22352942     DOI: 10.1021/mp200162b

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  6 in total

Review 1.  Traditional Chinese Medicine "Pill", an Ancient Dosage Form with Surprising Modern Pharmaceutical Characteristics.

Authors:  Jieyu Zuo; Chulhun Park; Janice Yu Chen Kung; Nádia Araci Bou-Chacra; Michael Doschak; Raimar Löbenberg
Journal:  Pharm Res       Date:  2021-02-18       Impact factor: 4.200

Review 2.  A Comprehensive Review of the Cardiovascular Protective Properties of Silibinin/Silymarin: A New Kid on the Block.

Authors:  Nikolaos P E Kadoglou; Chrystalla Panayiotou; Michail Vardas; Nikolaos Balaskas; Nikolaos G Kostomitsopoulos; Alexandra K Tsaroucha; Georgia Valsami
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

3.  Eremantholide C from aerial parts of Lychnophora trichocarpha, as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination.

Authors:  Tamires Guedes Caldeira; Dênia Antunes Saúde-Guimarães; Isabel González-Álvarez; Marival Bermejo; Jacqueline de Souza
Journal:  Daru       Date:  2021-04-22       Impact factor: 3.117

4.  Manufacturing Different Types of Solid Dispersions of BCS Class IV Polyphenol (Daidzein) by Spray Drying: Formulation and Bioavailability.

Authors:  Gean Pier Panizzon; Fernanda Giacomini Bueno; Tânia Ueda-Nakamura; Celso Vataru Nakamura; Benedito Prado Dias Filho
Journal:  Pharmaceutics       Date:  2019-09-25       Impact factor: 6.321

5.  Thiogenistein-Antioxidant Chemistry, Antitumor Activity, and Structure Elucidation of New Oxidation Products.

Authors:  Elżbieta U Stolarczyk; Weronika Strzempek; Marta Łaszcz; Andrzej Leś; Elżbieta Menaszek; Krzysztof Stolarczyk
Journal:  Int J Mol Sci       Date:  2022-07-15       Impact factor: 6.208

Review 6.  An Overview on Dietary Polyphenols and Their Biopharmaceutical Classification System (BCS).

Authors:  Francesca Truzzi; Camilla Tibaldi; Yanxin Zhang; Giovanni Dinelli; Eros D Amen
Journal:  Int J Mol Sci       Date:  2021-05-24       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.